Login to Your Account



AACR-NCI-EORTC International Conference

ALK Inhibition New Target in Inflammatory Breast Cancer

By Anette Breindl
Science Editor

Tuesday, November 15, 2011
One consequence of understanding the molecular underpinnings of cancer is that the disease has become increasingly fragmented. What was once a monolithic disorder is becoming, in one sense, a group of orphan diseases – a fact that has brought spectacular successes in the form of molecularly targeted therapies for some patients, but also brings obvious challenges for an industry still used to, or at least still pining for, blockbusters.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription